Canadian biotech company Asmacure has announced that Martin Driscoll will replace Luc Vachon as Chief Executive Officer. Vachon is leaving the company “to pursue other business ventures.” Asmacure is developing an inhaled nictonic receptor agonist, ASM-024, as a treatment for asthma.
Driscoll worked most recently as CEO of Javelin Pharmaceuticals, which merged with Hospira in 2010. According to Asmacure’s announcement, he also “spent a significant amount of time as general manager of Key Pharmaceuticals, the Schering unit responsible for all respiratory products marketed in the U.S.”
“I’m delighted to have joined a unique development company with such novel proprietary technology that has the potential to meet significant unmet medical needs and enhance current clinical practice,” said Mr. Driscoll; “The science that has been developed by the team at Asmacure under the leadership of Drs. Vachon and Cormier is truly impressive. I look forward to closely working with the talented Asmacure team as we lead the company through this exciting time of development and growth.”
